Senseonics Launches Eversense 365 in Europe, Expands Addressable Market but Execution and Funding Risks Persist

What happened

Senseonics announced the European launch of its one-year implantable CGM, Eversense 365, marking its first expansion outside the U.S. and targeting millions of new patients. While this validates the product's global appeal and opens a new revenue stream, the company is in the early stages of internalizing U.S. commercialization, a transition fraught with execution risk. The DeepValue report highlights that the stock already prices in aggressive growth, with a market cap of ~$289M and a negative earnings profile, requiring successful scaling to justify valuation. Despite revenue acceleration (2025 prelim $35.2M, +57% YoY) and 2026 guidance of $58-62M, the company faces a tight funding runway, with going-concern language and a need for additional capital. The EU launch adds a potential catalyst, but the investment case remains dependent on achieving ~50% gross margins and positive FCF, while avoiding dilutive financing that would erode per-share value.

Implication

The European launch of Eversense 365 expands the addressable market and provides a potential second revenue leg, but it does not resolve the core investment challenges: high cash burn, looming dilution risk from a $100M ATM and Hercules facility, and the untested in-house U.S. sales model. The DeepValue report assigns a 35% probability to a bear case where commercialization stalls, leading to revenues below $45M and forced equity financing, which would significantly impair per-share value. Even in the base case (45% probability), 2026 revenue of $55-60M and ~50% gross margins are needed to justify the current valuation of ~4.8x sales on negative EBITDA. The EU launch may improve the narrative and analyst sentiment, but given that the stock already prices in a successful growth ramp, any misstep in U.S. insourcing or funding could trigger a sharp re-rating. We maintain our WAIT rating and attractive entry of $4.50, preferring to wait for tangible evidence of margin expansion and a funded runway before committing capital.

Thesis delta

The EU launch partially validates the product's global demand but does not alter the central thesis that the company must execute an insourced U.S. commercialization while managing a precarious balance sheet. The key uncertainty remains whether Senseonics can achieve the guided $58-62M revenue and ~50% gross margins in 2026 without resorting to dilutive financing. We continue to see risk-reward as unfavorable at current prices until proof of execution and capital access materialize.